VSSI, Inc. introduces alternate in latch assemblies
VSSI, Inc., has introduced a new alternative in latch assemblies on the company’s 48-inch by 30-inch modular cage. The cage is now available with a latch that is designed to accommodate a padlock or door clip. The padlock latch is constructed of 12-gauge stainless steel, operates quietly, and is easily cleaned. A squeeze trigger latch is still being offered as a convenient, reliable choice. The 48-inch by 30-inch cage can be integrated into a variety of configurations to create a secure bank of cages. A divider kit for use with either latch design is available as an accessory.
www.vssi.com

Dechra’s VETORYL 10 mg capsules receive supplemental FDA approval
Dechra Veterinary Products LLC announced that it received supplemental FDA approval to market 10 mg VETORYL
Capsules. VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing’s syndrome in dogs. VETORYL is the only FDA-approved product that is indicated for use in pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s syndrome) in dogs. VETORYL is now approved in 10-, 30- and 60-mg capsules. VETORYL 30 mg and 60 mg capsules are currently available through veterinary distributors. The 10 mg capsules will be available in the near future.
www.dechra-us.com

IDEXX SNAPshot Dx® Analyzer’s testing capabilities expanded
IDEXX Laboratories, Inc. announced that the IDEXX SNAPshot Dx® Analyzer’s testing capabilities have been expanded to automatically time, interpret and record the SNAP® 4Dx® Test. This new capability, available with software version 1.11, extends the analyzer’s qualitative menu beyond the recently added SNAP® FIV/FeLV Combo Test and SNAP® cPL^TM Test, and the SNAP® T4, SNAP® Cortisol and SNAP® Bile Acids quantitative assays. IDEXX plans to continue to add other members of the SNAP® family of tests to the SNAPshot Dx Analyzer’s testing capabilities as the year progresses.
www.idexx.com

IDEXX LabREXX® Software launches within the newest release of the ImproMed® Infinity Practice Management System
IDEXX Reference Laboratories and ImproMed, Inc. have teamed up to launch IDEXX LabREXX® Software within the newest release of the ImproMed® Infinity Practice Management System. Incorporating LabREXX functionality into Infinity software increases practice efficiency by eliminating the need for manual test requisitions. Additionally, LabREXX software helps reduce lost charges with outside lab tests, potentially saving individual practices thousands of dollars a year in missed revenue.
www.idexx.com

Invernet/Schering-Plough Nobivac^TM Lyme
Intervet/Schering-Plough Animal Health introduced the Nobivac^TM Lyme. This new-generation Lyme vaccine is the only vaccine specifically designed to provide protection by targeting two key outer surface proteins involved in the transmission of canine Lyme disease. The vaccine induces the production of highly specific antibodies, called borreliacidal antibodies, that kill Borrelia burgdorferi (the causative agent of Lyme disease) by binding to outer surface proteins (Osp) A and C. The unique dual-action of Nobivac^TM Lyme provides an additional layer of defense against Lyme disease. Nobivac Lyme is administered by giving two doses subcutaneously, two to four weeks apart, with an annual booster thereafter. (Data supporting one-year duration of immunity are on file with the U.S. Department of Agriculture.) Safety studies demonstrated virtually no site reactions.
www.intervetusa.com

Intervet/Schering-Plough vaccine for canine influenza virus
Intervet/Schering-Plough Animal Health announced the availability of the first vaccine against canine influenza virus (CIV), which was granted a conditional product license by the U.S. Department of Agriculture (USDA) on May 27, 2009, for use by veterinarians in the United States. Canine influenza (CIV) has been detected in dogs in 30 states and the District of Columbia, according to Dr. Cynda Crawford, DVM., Ph.D., University of Florida, Clinical Assistant Professor of Shelter Medicine; and Edward J. Dubovi, Ph.D., Professor of Virology, Cornell University College of Veterinary Medicine, two of the nation’s leading experts on Canine H3N8. Most dogs have no immunity to canine influenza because it is a novel pathogen and, therefore, the infection can spread quickly through animal shelters, pet stores, boarding kennels, vet clinics and any location where dogs congregate. According to the U.S. Centers for Disease Control and Prevention (CDC), there is no evidence of transmission of the virus from dogs to people. Canine Influenza Vaccine, H3N8, has been demonstrated to reduce the incidence and severity of lung lesions, as well as the duration of coughing and viral shedding. It is administered by subcutaneous injection in two doses, two to four weeks apart. It may be given to dogs six weeks of age or older and can be given annually as a component of existing respiratory disease vaccine protocols to ensure more comprehensive protection.
www.intervetusa.com

Vetericyn Inc. launches equine wound, infection product
Vetericyn Inc. announced the launch of its new Vetericyn^TM equine product, available in a 16-ounce trigger spray for horses. Vetericyn^TM utilizes an FDA-cleared technology that has been used to successfully treat over 1 million human patients without a single serious adverse effect. Now, the innovative topical wound-care product is available to the animal healthcare market. Vetericyn^TM is the first non-toxic broad-spectrum antimicrobial on the market. The landscape-altering wound and infection control technology works naturally with the animal’s immune system to kill bacteria (including staph and drug-resistant MRSA), viruses, fungi and spores without harming healthy tissue.
www.vetericyn.com